Sign In  |  Register  |  About Livermore  |  Contact Us

Livermore, CA
September 01, 2020 1:25pm
7-Day Forecast | Traffic

  • Search Hotels in Livermore

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

STAAR Surgical Company - Common Stock (NQ: STAA )

24.82 -0.16 (-0.64%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 20, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about STAAR Surgical Company - Common Stock

< Previous 1 2 3 4 5 6 Next >
Morgan Stanley Maintains Positive MedTech Outlook Despite Setbacks in 2024, Upgrades Intuitive Surgical And Stryker, Downgrades Nevro And Glaukos
Morgan Stanley upgrades key MedTech stocks, highlighting strong demand and growth potential, while downgrading others amid company-specific challenges. 
Via Benzinga
Investors should take note of NASDAQ:STAA, a growth stock that remains attractively priced.
Investors seeking growth at a reasonable cost should explore STAAR SURGICAL CO (NASDAQ:STAA). 
Via Chartmill
In the world of growth stocks, NASDAQ:STAA shines as a value proposition.
Investors should take note of NASDAQ:STAA, a growth stock that remains attractively priced. 
Via Chartmill
Exploring Staar Surgical's Earnings Expectations
Via Benzinga
Investors seeking growth at a reasonable cost should explore NASDAQ:STAA.
Looking for growth without the hefty price tag? Consider STAAR SURGICAL CO (NASDAQ:STAA). 
Via Chartmill
Analyst Scoreboard: 4 Ratings For Staar Surgical
Via Benzinga
Analyst Expectations For Staar Surgical's Future
Via Benzinga
A Glimpse Into The Expert Outlook On Staar Surgical Through 4 Analysts
Via Benzinga
Expert Outlook: Staar Surgical Through The Eyes Of 5 Analysts
Via Benzinga
For those who appreciate growth without the sticker shock, NASDAQ:STAA is worth considering.
Don't overlook NASDAQ:STAA—a stock with solid growth prospects and a reasonable valuation. 
Via Chartmill
STAA Stock Earnings: Staar Surgical Misses EPS, Beats Revenue for Q2 2024
STAA stock results show that Staar Surgical missed analyst estimates for earnings per share but beat on revenue for the second quarter of 2024. 
Via InvestorPlace
Trump Media & Technology And Grindr Were Among The 10 Biggest Mid-Cap Stock Gainers Last Week (June 23 - June 29): Are These In Your Portfolio?
Top performers last week: Tempus AI +30%, Enovix Corp +29%, Grindr Inc +27.5%, Trump Media +18.33%, Credo Tech +18.3%, Tecnoglass Inc +17.9%, STAAR Surgical +16.55%, RXO Inc +16.22%, Global-E Online... 
Via Benzinga
Topics Artificial Intelligence Government
Exposures Artificial Intelligence Political
Staar Surgical Stock Earns RS Rating Upgrade
On Thursday, lens maker Staar Surgical stock had its Relative Strength (RS) Rating upgraded to 87 from 77. 
Via Investor's Business Daily
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Analyst Scoreboard: 7 Ratings For Staar Surgical
Via Benzinga
What 7 Analyst Ratings Have To Say About Staar Surgical
Via Benzinga
Why Upstart Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
STAA Stock Earnings: Staar Surgical Misses EPS, Beats Revenue for Q1 2024
STAA stock results show that Staar Surgical missed analyst estimates for earnings per share but beat on revenue for the first quarter of 2024. 
Via InvestorPlace
In-Depth Examination Of 4 Analyst Recommendations For Staar Surgical
Via Benzinga
A Preview Of Staar Surgical's Earnings
Via Benzinga
Staar Surgical Stock Climbs The Leadership Ladder With Jump To 84 RS Rating
On Thursday, implantable lens maker Staar Surgical stock had its Relative Strength (RS) Rating upgraded to 84, up from 80 a day earlier. 
Via Investor's Business Daily
Apple To $210? Here Are 10 Top Analyst Forecasts For Thursday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. 
Via Benzinga
Eye Lens Maker STAAR Surgical Expects Q1 Sales To Beat Consensus
STAAR Surgical reports Q1 2024 net sales surpassing $77 million, with U.S. ICL sales hitting $5 million, the highest since FDA approval in 2022. CEO anticipates fiscal 2024 sales expected at the higher... 
Via Benzinga
Exposures Product Safety
Staar Surgical, A Lasik Rival, Just Crushed Quarterly Views; But Is Its 2026 Target Too Aggressive?
The company makes an implantable lens to help correct vision problems. 
Via Investor's Business Daily
Nvidia’s Market Cap Myopia: 3 Stocks Proving Size Isn’t Everything
These three alternatives to Nvidia stock combined are smaller than the chipmaker but are worth it when considering Nvidia's market cap. 
Via InvestorPlace
Why STAAR Surgical Shares Are Trading Higher By Around 13%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Shares of STAAR Surgical Company (NASDAQ: STAA) rose sharply during Thursday’s session after the company issued strong preliminary first-quarter net sales guidance. STAAR Surgical shares jumped 13.3%... 
Via Benzinga
Netflix To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Monday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. 
Via Benzinga
Why Mesoblast Shares Are Trading Higher By 13%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Shares of Mesoblast Limited (NASDAQ: MESO) rose sharply during Monday’s session after the company announced FDA support of an accelerated approval pathway for rexlemestrocel-L in end-stage heart... 
Via Benzinga
Exposures Product Safety
Insiders Buying KalVista Pharmaceuticals And 3 Other Stocks
Although U.S. stocks closed higher on Wednesday, there were a few notable insider trades. 
Via Benzinga
Earnings Scheduled For February 26, 2024
Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is projected to report quarterly earnings at $0.23 per share on revenue of $477.73 million. 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 Livermore.com & California Media Partners, LLC. All rights reserved.